For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, Centessa Pharmaceuticals plc ADR’s stock clocked out at $9.46, up 0.64% from its previous closing price of $9.40. In other words, the price has increased by $0.64 from its previous closing price. On the day, 2.25 million shares were traded. CNTA stock price reached its highest trading level at $9.5219 during the session, while it also had its lowest trading level at $8.7.
Ratios:
To gain a deeper understanding of CNTA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.00 and its Current Ratio is at 8.00. In the meantime, Its Debt-to-Equity ratio is 0.36 whereas as Long-Term Debt/Eq ratio is at 0.36.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on November 15, 2023, Upgraded its rating to Buy and sets its target price to $11 from $4 previously.
On October 26, 2023, Morgan Stanley Upgraded its rating to Equal-Weight which previously was Underweight and also upped its target price recommendation from $4 to $8.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 25 ’24 when Anderson Karen M. sold 51,160 shares for $11.88 per share. The transaction valued at 607,960 led to the insider holds 71,525 shares of the business.
Rotman Harris sold 4,267 shares of CNTA for $34,574 on Feb 01 ’24. The SVP Regulatory Affairs now owns 62,625 shares after completing the transaction at $8.10 per share. On Sep 20 ’23, another insider, Rotman Harris, who serves as the SVP Regulatory Affairs of the company, sold 37,484 shares for $6.29 each. As a result, the insider received 235,688 and left with 33,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CNTA now has a Market Capitalization of 948894784 and an Enterprise Value of 777437312. For the stock, the TTM Price-to-Sale (P/S) ratio is 135.22 while its Price-to-Book (P/B) ratio in mrq is 3.96. Its current Enterprise Value per Revenue stands at 113.445 whereas that against EBITDA is -4.547.
Stock Price History:
The Beta on a monthly basis for CNTA is 1.43, which has changed by 1.1210763 over the last 52 weeks, in comparison to a change of 0.22640884 over the same period for the S&P500. Over the past 52 weeks, CNTA has reached a high of $12.45, while it has fallen to a 52-week low of $3.96. The 50-Day Moving Average of the stock is -12.96%, while the 200-Day Moving Average is calculated to be 18.95%.
Shares Statistics:
It appears that CNTA traded 394.02K shares on average per day over the past three months and 365690 shares per day over the past ten days. A total of 98.77M shares are outstanding, with a floating share count of 59.77M. Insiders hold about 39.49% of the company’s shares, while institutions hold 36.11% stake in the company. Shares short for CNTA as of 1711584000 were 1738229 with a Short Ratio of 4.41, compared to 1709164800 on 1536581. Therefore, it implies a Short% of Shares Outstanding of 1738229 and a Short% of Float of 2.35.
Earnings Estimates
The current assessment of Centessa Pharmaceuticals plc ADR (CNTA) involves the perspectives of 3.0 analysts closely monitoring its market dynamics.On average, analysts expect EPS of -$0.42 for the current quarter, with a high estimate of -$0.4 and a low estimate of -$0.44, while EPS last year was -$0.53. The consensus estimate for the next quarter is -$0.45, with high estimates of -$0.41 and low estimates of -$0.49.
Analysts are recommending an EPS of between -$1.64 and -$2.01 for the fiscal current year, implying an average EPS of -$1.81. EPS for the following year is -$1.86, with 2.0 analysts recommending between -$1.84 and -$1.88.
